Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Elizabeth C. Wescott,Xiaopeng Sun,Paula Gonzalez-Ericsson,Ann Hanna,Brandie C. Taylor,Violeta Sanchez,Juliana Bronzini,Susan R. Opalenik,Melinda E. Sanders,Julia Wulfkuhle,Rosa I. Gallagher,Henry Gomez,Claudine Isaacs,Vijaya Bharti,John T. Wilson,Tarah J. Ballinger,Cesar A. Santa-Maria,Payal D. Shah,Elizabeth C. Dees,Brian D. Lehmann,Vandana G. Abramson,Gillian L. Hirst,Lamorna Brown Swigart,Laura J. van ˈt Veer,Laura J. Esserman,Emanuel F. Petricoin,Jennifer A. Pietenpol,Justin M. Balko
DOI: https://doi.org/10.1158/2767-9764.crc-23-0468
2024-04-25
Cancer Research Communications
Abstract:Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to identify regulation mechanisms of B7-H4 in vitro. We used an immunocompetent anti-PD-L1–sensitive orthotopic mammary cancer model and induced ectopic expression of B7-H4. We assessed therapy response and transcriptional changes at baseline and under treatment with anti-PD-L1. We observed B7-H4 was highly associated with epithelial cell status and transcription factors and found to be regulated by PI3K activity. EMT6 tumors with cell-surface B7-H4 expression were more resistant to immunotherapy. In addition, tumor-infiltrating immune cells had reduced immune activation signaling based on transcriptomic analysis. Paradoxically, in human breast cancer, B7-H4 expression was associated with survival benefit for patients with metastatic TNBC treated with carboplatin plus anti-PD-L1 and was associated with no change in response or survival for patients with early breast cancer receiving chemotherapy plus anti-PD-1. While B7-H4 induces tumor resistance to anti-PD-L1 in murine models, there are alternative mechanisms of signaling and function in human cancers. In addition, the strong correlation of B7-H4 to epithelial cell markers suggests a potential regulatory mechanism of B7-H4 independent of PD-L1. Significance: This translational study confirms the association of B7-H4 expression with a cold immune microenvironment in breast cancer and offers preclinical studies demonstrating a potential role for B7-H4 in suppressing response to checkpoint therapy. However, analysis of two clinical trials with checkpoint inhibitors in the early and metastatic settings argue against B7-H4 as being a mechanism of clinical resistance to checkpoints, with clear implications for its candidacy as a therapeutic target.